Reversible posterior leucoencephalopathy during oral treatment with methotrexate.
Dimitri
D
Renard
Rene
R
Westhovens
Erik
E
Vandenbussche
Rik
R
Vandenberghe
D020237:Alexia, Pure / Q000139:chemically induced / Q000473:pathology / Q000503:physiopathology; D018501:Antirheumatic Agents / Q000009:adverse effects*; D015535:Arthritis, Psoriatic / Q000188:drug therapy; D004333:Drug Administration Routes; D004334:Drug Administration Schedule; D004409:Dyskinesia, Drug-Induced / Q000473:pathology / Q000503:physiopathology; D005260:Female; D006801:Humans; D008279:Magnetic Resonance Imaging; D008569:Memory Disorders / Q000139:chemically induced / Q000473:pathology / Q000503:physiopathology; D008727:Methotrexate / Q000009:adverse effects*; D008875:Middle Aged; D020258:Neurotoxicity Syndromes / Q000473:pathology / Q000503:physiopathology*; D009778:Occipital Lobe / Q000187:drug effects* / Q000473:pathology / Q000503:physiopathology*; D010468:Perceptual Disorders / Q000139:chemically induced / Q000473:pathology / Q000503:physiopathology; D020127:Recovery of Function; D014786:Vision Disorders / Q000139:chemically induced* / Q000473:pathology / Q000503:physiopathology; D014796:Visual Perception / Q000187:drug effects
D018501:Antirheumatic Agents; D008727:Methotrexate